Paget disease of bone: Diagnosis and drug therapy

Cleveland Clinic Journal of Medicine

Volumn 80, Issue 7, 2013, Pages 452-462

  Seton, Margaret ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ARTICLE; GENETIC PREDISPOSITION; HEALTH; HUMAN; PAGET BONE DISEASE; RISK FACTOR;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; OSTEITIS DEFORMANS; RISK FACTORS; WORLD HEALTH;

EID: 84880718145     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.80a.12142     Document Type: Article

References (72)

1. Paget J. On a form of chronic inflammation of bones (osteitis deformans). Med Chir Trans 1877; 60:37-64.9.
2. Guyer PB, Chamberlain AT, Ackery DM, Rolfe EB. The anatomic distribution of osteitis deformans. Clin Orthop Relat Res 1981; 156:141-144.
3. Tiegs RD, Lohse CM, Wollan PC, Melton LJ. Long-term trends in the incidence of Paget's disease of bone. Bone 2000; 27:423-427.
4. Altman RD, Bloch DA, Hochberg MC, Murphy WA. Prevalence of pelvic Paget's disease of bone in the United States. J Bone Miner Res 2000; 15:461-465.
5. Barker DJ. The epidemiology of Paget's disease of bone. Br Med Bull 1984; 40:396-400.
6. Detheridge FM, Guyer PB, Barker DJ. European distribution of Paget's disease of bone. Br Med J (Clin Res Ed) 1982; 285:1005-1008.
7. van Staa TP, Selby P, Leufkens HG, Lyles K, Sprafka JM, Cooper C. Incidence and natural history of Paget's disease of bone in England and Wales. J Bone Miner Res 2002; 17:465-471.
8. Barker DJ. The epidemiology of Paget's disease. Metab Bone Dis Relat Res 1981; 3:231-233.
9. Rogers J, Jeffrey DR, Watt I. Paget's disease in an archeological population. J Bone Miner Res 2002; 17:1127-1134.
10. Aaron JE, Rogers J, Kanis JA. Paleohistology of Paget's disease in two medieval skeletons. Am J Phys Anthropol 1992; 89:325-331.
11. Poór G, Donáth J, Fornet B, Cooper C. Epidemiology of Paget's disease in Europe: the prevalence is decreasing. J Bone Miner Res 2006; 21:1545-1549.
12. Cundy HR, Gamble G, Wattie D, Rutland M, Cundy T. Paget's disease of bone in New Zealand: continued decline in disease severity. Calcif Tissue Int 2004; 75:358-364.
13. Doyle T, Gunn J, Anderson G, Gill M, Cundy T. Paget's disease in New Zealand: evidence for declining prevalence. Bone 2002; 31:616-619.
14. Laurin N, Brown JP, Morissette J, Raymond V. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet 2002; 70:1582-1588.
15. Hocking LJ, Lucas GJ, Daroszewska A, et al. Domainspecific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease. Hum Mol Genet 2002; 11:2735-2739.
16. Lucas GJ, Hocking LJ, Daroszewska A, et al. Ubiquitin-associated domain mutations of SQSTM1 in Paget's disease of bone: evidence for a founder effect in patients of British descent. J Bone Miner Res 2005; 20:227-231.
17. Mays S. Archaeological skeletons support a northwest European origin for Paget's disease of bone. J Bone Miner Res 2010; 25:1839-1841.
18. Bolland MJ, Tong PC, Naot D, et al. Delayed development of Paget's disease in offspring inheriting SQSTM1 mutations. J Bone Miner Res 2007; 22:411-415.
19. Rea SL, Walsh JP, Ward L, et al. A novel mutation (K378X) in the sequestosome 1 gene associated with increased NF-kappaB signaling and Paget's disease of bone with a severe phenotype. J Bone Miner Res 2006; 21:1136-1145.
20. Morissette J, Laurin N, Brown JP. Sequestosome 1: mutation frequencies, haplotypes, and phenotypes in familial Paget's disease of bone. J Bone Miner Res 2006; 21(suppl 2):P38-P44.
21. EekhoffEW, Karperien M, Houtsma D, et al. Familial Paget's disease in The Netherlands: occurrence, identification of new mutations in the sequestosome 1 gene, and their clinical associations. Arthritis Rheum 2004; 50:1650-1654.
22. Ralston SH, Layfield R. Pathogenesis of Paget disease of bone. Calcif Tissue Int 2012; 91:97-113.
23. Kurihara N, Hiruma Y, Yamana K, et al. Contributions of the measles virus nucleocapsid gene and the SQSTM1/p62(P392L) mutation to Paget's disease. Cell Metab 2011; 13:23-34.
24. Kurihara N, Zhou H, Reddy SV, et al. Expression of measles virus nucleocapsid protein in osteoclasts induces Paget's disease-like bone lesions in mice. J Bone Miner Res 2006; 21:446-455.
25. Reddy SV, Singer FR, Roodman GD. Bone marrow mononuclear cells from patients with Paget's disease contain measles virus nucleocapsid messenger ribonucleic acid that has mutations in a specific region of the sequence. J Clin Endocrinol Metab 1995; 80:2108-2111.
26. Gennari L, Merlotti D, Martini G, Nuti R. Paget's disease of bone in Italy. J Bone Miner Res 2006; 21(suppl 2):P14-P21.
27. Seton M, Choi HK, Hansen MF, Sebaldt RJ, Cooper C. Analysis of environmental factors in familial versus sporadic Paget's disease of bone-the New England Registry for Paget's Disease of Bone. J Bone Miner Res 2003; 18:1519-1524.
28. Siris ES. Extensive personal experience: Paget's disease of bone. J Clin Endocrinol Metab 1995; 80:335-338.
29. Lucas GJ, Daroszewska A, Ralston SH. Contribution of genetic factors to the pathogenesis of Paget's disease of bone and related disorders. J Bone Miner Res 2006; 21(suppl 2):P31-P37.
30. Seton M. Diagnosis, complications and treatment of Paget's disease of bone. Aging Health 2009; 5:497-508.
31. Siris E, Roodman GD. Paget's Disease of Bone. 7th ed. Washington, DC: American Society for Bone and Mineral Research; 2008.
32. Seton M, Moses AM, Bode RK, Schwartz C. Paget's disease of bone: the skeletal distribution, complications and quality of life as perceived by patients. Bone 2011; 48:281-285.
33. Seton M. Paget's disease of bone. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors. Rheumatology. 5th ed. Philadelphia, PA: Mosby Elsevier; 2010:2021-2028.
34. Douglas DL, Duckworth T, Kanis JA, Jefferson AA, Martin TJ, Russell RG. Spinal cord dysfunction in Paget's disease of bone. Has medical treatment a vascular basis? J Bone Joint Surg Br 1981; 63B:495-503.
35. Siris ES. Epidemiological aspects of Paget's disease: family history and relationship to other medical conditions. Semin Arthritis Rheum 1994; 23:222-225.
36. Kanis JA, Evanson JM, Russell RG. Paget's disease of bone: diagnosis and management. Metab Bone Dis Relat Res 1981; 3:219-230.
37. Mangham DC, Davie MW, Grimer RJ. Sarcoma arising in Paget's disease of bone: declining incidence and increasing age at presentation. Bone 2009; 44:431-436.
38. Hansen MF, Seton M, Merchant A. Osteosarcoma in Paget's disease of bone. J Bone Miner Res 2006; 21(suppl 2):P58-P63.
39. Price CH. The incidence of osteogenic sarcoma in South- West England and its relationship to Paget's disease of bone. J Bone Joint Surg Br 1962; 44-B:366-376.
40. Ishikawa Y, Tsukuma H, Miller RW. Low rates of Paget's disease of bone and osteosarcoma in elderly Japanese. Lancet 1996; 347:1559.
41. Sun SG, Lau YS, Itonaga I, Sabokbar A, Athanasou NA. Bone stromal cells in pagetic bone and Paget's sarcoma express RANKL and support human osteoclast formation. J Pathol 2006; 209:114-120.
42. Rendina D, Gennari L, De Filippo G, et al. Evidence for increased clinical severity of familial and sporadic Paget's disease of bone in Campania, southern Italy. J Bone Miner Res 2006; 21:1828-1835.
43. Fenton P, Resnick D. Metastases to bone affected by Paget's disease. A report of three cases. Int Orthop 1991; 15:397-399.
44. Tu SM, Som A, Tu B, Logothetis CJ, Lee MH, Yeung SC. Effect of Paget's disease of bone (osteitis deformans) on the progression of prostate cancer bone metastasis. Br J Cancer 2012; 107:646-651.
45. EekhoffME, van der Klift M, Kroon HM, et al. Paget's disease of bone in The Netherlands: a population-based radiological and biochemical survey-the Rotterdam Study. J Bone Miner Res 2004; 19:566-570.
46. Reid IR, Davidson JS, Wattie D, et al. Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone. Bone 2004; 35:224-230.
47. Alvarez L, Guañabens N, Peris P, et al. Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget's disease. Bone 2001; 29:447-452.
48. Cundy T, Reid IR. Paget's disease of bone. Clin Biochem 2012; 45:43-48.
49. Cortis K, Micallef K, Mizzi A. Imaging Paget's disease of bone-from head to toe. Clin Radiol 2011; 66:662-672.
50. Redden JF, Dixon J, Vennart W, Hosking DJ. Management of fissure fractures in Paget's disease. Int Orthop 1981; 5:103-106.
51. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 25-1993. A 67-year-old man with osteolytic lesions of T11 and T12. N Engl J Med 1993; 328:1836-1841.
52. Evans RA, Dunstan CR, Hills E, Wong SY. Pathologic fracture due to severe osteomalacia following low-dose diphosphonate treatment of Paget's disease of bone. Aust N Z J Med 1983; 13:277-279.
53. Siris E, Weinstein RS, Altman R, et al. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab 1996; 81:961-967.
54. Reid IR, Siris E. Alendronate in the treatment of Paget's disease of bone. Int J Clin Pract Suppl 1999; 101:62-66.
55. Miller PD, Brown JP, Siris ES, Hoseyni MS, Axelrod DW, Bekker PJ. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group. Am J Med 1999; 106:513-520.
56. Peris P, Alvarez L, Vidal S, Martínez MA, Monegal A, Guañabens N. Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy. Clin Exp Rheumatol 2007; 25:206-210.
57. Reid IR, Miller P, Lyles K, et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med 2005; 353:898-908.
58. Reid IR, Lyles K, Su G, et al. A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years. J Bone Miner Res 2011; 26:2261-2270.
59. Langston AL, Campbell MK, Fraser WD, MacLennan GS, Selby PL, Ralston SH; PRISM Trial Group. Randomized trial of intensive bisphosphonate treatment versus symptomatic management in Paget's disease of bone. J Bone Miner Res 2010; 25:20-31.
60. Abrahamsen B, Einhorn TA. Beyond a reasonable doubt? Bisphosphonates and atypical femur fractures. Bone 2012; 50:1196-1200.
61. Seton M, Krane SM. Use of zoledronic acid in the treatment of Paget's disease. Ther Clin Risk Manag 2007; 3:913-918.
62. Sørensen HT, Christensen S, Mehnert F, et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: Population based case-control study. BMJ 2008; 336:813-816.
63. Dixon WG, Solomon DH. Bisphosphonates and esophageal cancer-a pathway through the confusion. Nat Rev Rheumatol 2011; 7:369-372.
64. Singer FR, Krane SM. Paget's disease of bone. In: Avioli LV, Krane SM, editors. Metabolic Bone Disease and Clinically Related Disorders. 2nd ed. Philadelphia, PA: W.B. Saunders Company; 1990:546-615.
65. Kanis JA, Horn DB, Scott RD, Strong JA. Treatment of Paget's disease of bone with synthetic salmon calcitonin. Br Med J 1974; 3:727-731.
66. Schwarz P, Rasmussen AQ, Kvist TM, Andersen UB, Jørgensen NR. Paget's disease of the bone after treatment with denosumab: a case report. Bone 2012; 50:1023-1025.
67. Adami S, Bartolozzi P, Brandi ML, et al; Societa Italiana di Ortopedia e Traumatologia; Societa Italiana di Osteoporosi e Malattie del Metabolismo Minerale e Scheletrico; Societa Italiana di Reumatologia. [Italian guidelines for the diagnosis and treatment of Paget's disease of bone.] Reumatismo 2007; 59:153-168. (Article in Italian.)
68. Scarsbrok A, Brown M, Wilson D. UK guidelines on management of Paget's disease of bone. Rheumatology (Oxford) 2004; 43:399-400.
69. Takata S, Hashimoto J, Nakatsuka K, et al. Guidelines for diagnosis and management of Paget's disease of bone in Japan. J Bone Miner Metab 2006; 24:359-367.
70. Josse RG, Hanley DA, Kendler D, Ste Marie L-G, Adachi JD, Brown J. Diagnosis and treatment of Paget's disease of bone. Clin Invest Med 2007; 30:E210-E223.
71. Kaplan FS. Paget's disease of bone: orthopedic complications. Semin Arthritis Rheum 1994; 23:250-252.
72. Kanis JA, Gray RE. Long-term follow-up observations on treatment in Paget's disease of bone. Clin Orthop Relat Res 1987; 217:99-125.